De-novo hepatocellular carcinoma after pediatric living donor liver transplantation

Table 1 Modified from Saab et al[14]

Patient	Ref.	OLT indication	Age	Gender	Immunosuppression	Interval (yr)	Type of donor	PVS	Approach after de-novo HCC
1	Saxena et al[4]	HCV and ALD	63	M	CYA, AZA and Pred	7	DD	Yes	Retransplant
2	Levitsky et al[5]	HCV and ALD	48	M	CYA, AZA and Pred	5	N/A	Yes	NR
3	Croitoru et al[6]	HCV and NAFLD	61	M	CYA and Pred	6	DD	Yes	Retransplant
4	Flemming et al[7]	HBV	NR	M	NR	9	DD	Yes	Hepatic Resection
5	Flemming et al[7]	HBV	NR	M	NR	8	DD	Yes	Retransplant and Hepatic Resection
6	Torbenson et al[8]	HBV	51	M	NR	8.5	DD	Yes	Retransplant
7	Kita et al[9]	HBV	43	M	NR	14	NA	Yes	Retransplant
8	Yu et al[10]	HBV	36	M	TAC, MMF andPred	2	LD	Yes	RFA
9	Sotiropoulos et al[11]	Budd-Chiari Syndrome	61	F	NR	22	NA	Yes	TACE
10	Sotiropoulos et al[11]	ALD	65	M	NR	5	NA	NR	RFA
11	Vernadakis et al[12]	ALD	59	M	CYA, MMF and Pred	3	DD	No	Hepatic Resection
12	Tamè et al[13]	HCV	54	M	TAC and Pred	6	DD	Yes	TACE
13	Saab et al[14]	HCV	47	F	TAC and MMF	19	-	Yes	TACE, RFA, Sorafenib, Retransplant
14	Tamè et al[13]	SSC	44	M	TAC and Pred	6	DD	Yes	Sorafenib
15	Navarro Burgos et al[15]	HCV and HBV	45	M	NR	0.75	DD	Yes	TACE
16	The present case	Biliary atresia	29	M	TAC and Sirolimus	14	LD	No	PMWA

OLT: Orthotropic liver transplantation; DD: Deceased donor; LD: Living donor; PVS: Positive viral serology; HCV: Hepatitis C virus; SSC: Secondary sclerosing cholangitis; ALD: Alcoholic liver disease; NAFLD: Non-alcoholic fatty liver disease; HBV: Hepatitis B virus; NR: Not reported; CYA: Cyclophosphamide; AZA: Azathioprine; Pred: Prednisone; TAC: Tacrolimus; MMF: Mycophenolate mofetil; RFA: Radiofrequency ablation; TACE: Transarterial chemoembolization; PMWA: Percutaneous microwave ablation; M: Male; F: Female; NA: Not available.